ANDA 89027, held by Watson Laboratories. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89027 (Procainamide Hydrochloride), held by Watson Laboratories, was first approved by FDA on Oct 22, 1985, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 1985 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG · tablet, extended release;oral | Procainamide Hydrochloride | Discontinued |
| Jun 8, 1998 | Supplement 9Manufacturing | Approved | None posted |
| Dec 16, 1991 | Supplement 8Labeling | Approved | None posted |
| Aug 30, 1991 | Supplement 7Labeling | Approved | None posted |
| Aug 7, 1991 | Supplement 5Manufacturing | Approved | None posted |
| Jan 28, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Jan 12, 1989 | Supplement 4Labeling | Approved | None posted |
| Oct 23, 1986 | Supplement 1Manufacturing | Approved | None posted |
| Oct 23, 1986 | Supplement 2Manufacturing | Approved | None posted |
| Oct 22, 1985 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters